According to the latest report by IMARC Group, titled “Biopharmaceutical Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global biopharmaceutical manufacturing market size reached 5.4 Million Liters in 2018. Biopharmaceutical manufacturing is a highly complex research and development process involving considerable investments in terms of capital and time to build specialized manufacturing facilities and equipment. An increase in the demand for biosimilars, which are useful in the treatment of various chronic diseases, has led to the introduction of new and improved manufacturing techniques. They have helped in reducing costs, increasing efficiencies and improving weak development pipelines, especially in the developing regions.
Global Biopharmaceutical Manufacturing Market Trends:
Nowadays, the vast majority of the global population suffers from acute diseases, resulting in the rising demand for biopharmaceutical drugs. This has prompted the leading companies to produce these medicines on a larger scale. Besides this, significant advancements have been made in the fields of medical science and engineering over the past few decades, which have enabled the implementation of continuous pharmaceutical manufacturing. The increasing healthcare spending has further led to the development of international biomanufacturing centers that focus on single-use technology. This helps in improving operational costs by increasing process flexibility and offering higher product yield. Additionally, the use of this technology helps in creating a greener manufacturing platform as it tends to consume fewer raw materials, water and utilities and has a smaller carbon footprint than traditional processing. Moreover, several companies are outsourcing various production activities to contract manufacturers due to the significant cost savings, innovation and specific capabilities offered by them. Looking forward, the market is projected to witness moderate growth during 2019-2024.
- Based on the cell culture, the market has been segmented into mammalian and microbial cell cultures. At present, mammalian cell culture represents the largest category, holding the majority of the market share.
- Based on the class, the report finds that recombinant proteins dominate the market. Other major segments are monoclonal antibodies, interferon, erythropoietin, granulocyte colony-stimulating factor (G-CSF), recombinant human insulin, vaccines and human growth hormones (HGH).
- Region-wise, North America currently represents the largest market, accounting for nearly half of the total market share. Other major regions include Europe and Asia Pacific.
- The competitive landscape of the market has also been examined with some of the key players being F. Hoffmann-La Roche AG, Amgen Inc., Novo Nordisk A/S, AbbVie, Inc., Sanofi S.A, Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., Eli Lilly and Company, and Biogen Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Follow us on twitter : @imarcglobal